Systematic review: The effects of autologous stem cell therapy for patients with liver disease

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 7, 2014, Pages 673-685

  Moore, J K ^a   Stutchfield, B M ^a   Forbes, S J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; HYALURONIC ACID; LAMININ;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; CASE CONTROL STUDY; CHILD PUGH SCORE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; FEASIBILITY STUDY; FOLLOW UP; HEPATIC ARTERY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; LIVER FUNCTION TEST; MODEL FOR END STAGE LIVER DISEASE SCORE; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; REVIEW; SAFETY; SYSTEMATIC REVIEW;

HUMANS; LIVER DISEASES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84903362698     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12645     Document Type: Review

References (71)

1. Zatonski WA, Sulkowska U, Manczuk M, et al,. Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe. Eur Addict Res 2010; 16: 193-201.
2. D'Amico G, Garcia-Tsao G, Pagliaro L,. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-31.
3. Goldberg D, French B, Trotter J, et al,. Underreporting of liver transplant waitlist removals due to death or clinical deterioration: results at four major centers. Transplantation 2013; 96: 211-6.
4. Korbling M, Estrov Z,. Adult stem cells for tissue repair-A new therapeutic concept? N Engl J Med 2003; 349: 570-82.
5. Weissman IL,. Stem cells: units of development, units of regeneration, and units in evolution. Cell 2000; 100: 157-68.
6. Yin AH, Miraglia S, Zanjani ED, et al,. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 5002-12.
7. Krause DS, Fackler MJ, Civin CI, May WS,. CD34: structure, biology, and clinical utility. Blood 1996; 87: 1-13.
8. Handgretinger R, Gordon PR, Leimig T, et al,. Biology and plasticity of CD133+ hematopoietic stem cells. Ann N Y Acad Sci 2003; 996: 141-51.
9. Dominici M, Le Blanc K, Mueller I, et al,. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-7.
10. Piscaglia AC, Campanale M, Gasbarrini A, Gasbarrini G,. Stem cell-based therapies for liver diseases: state of the art and new perspectives. Stem Cells Int 2010; 2010: 259461.
11. Alison M, Golding M, el Lalani N, Sarraf C,. Wound healing in the liver with particular reference to stem cells. Philos Trans R Soc Lond B Biol Sci 1998; 353: 877-94.
12. Fausto N,. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology 2004; 39: 1477-87.
13. Thorgeirsson SS,. Hepatic stem cells in liver regeneration. FASEB J 1996; 10: 1249-56.
14. Gupta S, Gorla GR, Irani AN,. Hepatocyte transplantation: emerging insights into mechanisms of liver repopulation and their relevance to potential therapies. J Hepatol 1999; 30: 162-70.
15. Togel F, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C,. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007; 292: F1626-35.
16. Alison MR, Poulsom R, Jeffery R, et al,. Hepatocytes from non-hepatic adult stem cells. Nature 2000; 406: 257.
17. Theise ND, Badve S, Saxena R, et al,. Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation. Hepatology 2000; 31: 235-40.
18. Vassilopoulos G, Wang PR, Russell DW,. Transplanted bone marrow regenerates liver by cell fusion. Nature 2003; 422: 901-4.
19. Quintana-Bustamante O, Alvarez-Barrientos A, Kofman AV, et al,. Hematopoietic mobilization in mice increases the presence of bone marrow-derived hepatocytes via in vivo cell fusion. Hepatology 2006; 43: 108-16.
20. Gruh I, Martin U,. Transdifferentiation of stem cells: a critical view. Adv Biochem Eng Biotechnol 2009; 114: 73-106.
21. Higgins JPT, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration. 2011. Available at: www.cochrane-handbook.org.
22. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC,. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-71.
23. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R,. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
24. Kapetanos D, Yannaki E, Anagnostopoulis A, et al,. Lasting amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilzed peripheral blood stem cells. AASLD Conference 2007; Abstract 826.
25. Brodosi L, Catani L, Lorenzini S, et al,. CD133+ stem cells for the treatment of end stage liver disease. J Hepatol 2012; 56 (Suppl. 2): S163.
26. El Ansary M, Mogawer S, Elhamid SA, et al,. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. J Cancer Res Clin Oncol 2013; 139: 39-48.
27. am Esch JS, Schmelzle M, Furst G, et al,. Infusion of CD133+ bone marrow-derived stem cells after selective portal vein embolization enhances functional hepatic reserves after extended right hepatectomy: a retrospective single-center study. Ann Surg 2012; 255: 79-85.
28. El-Ansary M, Abdel-Aziz I, Mogawer S, et al,. Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev 2012; 8: 972-81.
29. Zhang Z, Lin H, Shi M, et al,. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol 2012; 27 (Suppl. 2): 112-20.
30. Couto BG, Goldenberg RC, da Fonseca LM, et al,. Bone marrow mononuclear cell therapy for patients with cirrhosis: a phase 1 study. Liver Int 2011; 31: 391-400.
31. Amer ME, El-Sayed SZ, El-Kheir WA, et al,. Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells. Eur J Gastroenterol Hepatol 2011; 23: 936-41.
32. Nikeghbalian S, Pournasr B, Aghdami N, et al,. Autologous transplantation of bone marrow-derived mononuclear and CD133(+) cells in patients with decompensated cirrhosis. Arch Iran Med 2011; 14: 12-7.
33. Peng L, Xie DY, Lin BL, et al,. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology 2011; 54: 820-8.
34. Saito T, Okumoto K, Haga H, et al,. Potential therapeutic application of intravenous autologous bone marrow infusion in patients with alcoholic liver cirrhosis. Stem Cells Dev 2011; 20: 1503-10.
35. Lyra AC, Soares MB, da Silva LF, et al,. Infusion of autologous bone marrow mononuclear cells through hepatic artery results in a short-term improvement of liver function in patients with chronic liver disease: a pilot randomized controlled study. Eur J Gastroenterol Hepatol 2010; 22: 33-42.
36. Ismail A, Fouad O, Abdelnasser A, Chowdhury A, Selim A,. Stem cell therapy improves the outcome of liver resection in cirrhotics. J Gastrointest Cancer 2010; 41: 17-23.
37. Kharaziha P, Hellstrom PM, Noorinayer B, et al,. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol 2009; 21: 1199-205.
38. Pai M, Zacharoulis D, Milicevic MN, et al,. Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol 2008; 103: 1952-8.
39. Han Y, Yan L, Han G, et al,. Controlled trials in hepatitis B virus-related decompensate liver cirrhosis: peripheral blood monocyte transplant versus granulocyte-colony-stimulating factor mobilization therapy. Cytotherapy 2008; 10: 390-6.
40. Khan AA, Parveen N, Mahaboob VS, et al,. Safety and efficacy of autologous bone marrow stem cell transplantation through hepatic artery for the treatment of chronic liver failure: a preliminary study. Transplant Proc 2008; 40: 1140-4.
41. Levicar N, Dimarakis I, Flores C, Tracey J, Gordon MY, Habib NA,. Stem cells as a treatment for chronic liver disease and diabetes. Handb Exp Pharmacol 2007; 180: 243-62.
42. Furst G, Schulte am Esch J, Poll LW, et al,. Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience. Radiology 2007; 243: 171-9.
43. Terai S, Ishikawa T, Omori K, et al,. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 2006; 24: 2292-8.
44. Yannaki E, Anagnostopoulos A, Kapetanos D, et al,. Lasting amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells. Exp Hematol 2006; 34: 1583-7.
45. am Esch JS 2nd, Knoefel WT, Klein M, et al,. Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 2005; 23: 463-70.
46. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF,. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 2005; 28: 496-504.
47. Palmer DH, Midgley RS, Mirza N, et al,. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009; 49: 124-32.
48. Spahr L, Chalandon Y, Terraz S, et al,. Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial. PLoS ONE 2013; 8: e53719.
49. Takami T, Terai S, Sakaida I,. Novel findings for the development of drug therapy for various liver diseases: current state and future prospects for our liver regeneration therapy using autologous bone marrow cells for decompensated liver cirrhosis patients. J Pharmacol Sci 2011; 115: 274-8.
50. Salama H, Zekri AR, Bahnassy AA, et al,. Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease. World J Gastroenterol 2010; 16: 5297-305.
51. Lyra AC, Soares MB, da Silva LF, et al,. Feasibility and safety of autologous bone marrow mononuclear cell transplantation in patients with advanced chronic liver disease. World J Gastroenterol 2007; 13: 1067-73.
52. Mohamadnejad M, Namiri M, Bagheri M, et al,. Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World J Gastroenterol 2007; 13: 3359-63.
53. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, et al,. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med 2007; 10: 459-66.
54. Kim JK, Park YN, Kim JS, et al,. Autologous bone marrow infusion activates the progenitor cell compartment in patients with advanced liver cirrhosis. Cell Transplant 2010; 19: 1237-46.
55. Iwashita Y, Tahara K, Goto S, et al,. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 2003; 52: 155-61.
56. Salama H, Zekri AR, Zern M, et al,. Autologous hematopoietic stem cell transplantation in 48 patients with end-stage chronic liver diseases. Cell Transplant 2010; 19: 1475-86.
57. Ladhams A, Schmidt C, Sing G, et al,. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002; 17: 889-96.
58. Levicar N, Pai M, Habib NA, et al,. Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+ cells in patients with chronic liver disease. Cell Prolif 2008; 41 (Suppl. 1): 115-25.
59. Gordon MY, Levicar N, Pai M, et al,. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells 2006; 24: 1822-30.
60. Russo FP, Alison MR, Bigger BW, et al,. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 2006; 130: 1807-21.
61. Kumar M, Zhao X, Wang XW,. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci 2011; 1: 5.
62. Wu XZ, Chen D,. Origin of hepatocellular carcinoma: role of stem cells. J Gastroenterol Hepatol 2006; 21: 1093-8.
63. Spahr L, Lambert JF, Rubbia-Brandt L, et al,. Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology 2008; 48: 221-9.
64. Garg V, Garg H, Khan A, et al,. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 2012; 142: 505-12.
65. Lorenzini S, Isidori A, Catani L, et al,. Stem cell mobilization and collection in patients with liver cirrhosis. Aliment Pharmacol Ther 2008; 27: 932-9.
66. Piscaglia AC, Shupe TD, Oh SH, Gasbarrini A, Petersen BE,. Granulocyte-colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats. Gastroenterology 2007; 133: 619-31.
67. Liu F, Pan X, Chen G, et al,. Hematopoietic stem cells mobilized by granulocyte colony-stimulating factor partly contribute to liver graft regeneration after partial orthotopic liver transplantation. Liver Transpl 2006; 12: 1129-37.
68. Russo FP, Parola M,. Stem cells in liver failure. Best Pract Res Clin Gastroenterol 2012; 26: 35-45.
69. Lodi D, Iannitti T, Palmieri B,. Stem cells in clinical practice: applications and warnings. J Exp Clin Cancer Res 2011; 30: 9.
70. Forbes SJ, Newsome PN,. New horizons for stem cell therapy in liver disease. J Hepatol 2012; 56: 496-9.
71. Houlihan DD, Newsome PN,. Critical review of clinical trials of bone marrow stem cells in liver disease. Gastroenterology 2008; 135: 438-50.